Sutro Biopharma, Inc. (STRO)

NASDAQ: STRO · IEX Real-Time Price · USD
4.44
0.06 (1.37%)
At close: May 27, 2022 4:00 PM
4.59
0.15 (3.38%)
After-hours:May 27, 2022 5:21 PM EDT
Market Cap211.24M
Revenue (ttm)53.12M
Net Income (ttm)-114.29M
Shares Out47.58M
EPS (ttm)-2.47
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume540,110
Open4.41
Previous Close4.38
Day's Range4.17 - 4.52
52-Week Range4.17 - 23.70
Beta1.10
AnalystsBuy
Price Target29.84 (+572.1%)
Earnings DateMay 6, 2022

About STRO

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate rec...

IndustryBiotechnology
IPO DateSep 27, 2018
CEOWilliam Newell
Employees234
Stock ExchangeNASDAQ
Ticker SymbolSTRO
Full Company Profile

Financial Performance

In 2021, STRO's revenue was $61.88 million, an increase of 44.84% compared to the previous year's $42.72 million. Losses were -$105.54 million, 228.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for STRO stock is "Buy." The 12-month stock price forecast is 29.84, which is an increase of 572.07% from the latest price.

Price Target
$29.84
(572.07% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Misses Revenue Estimates

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -6.33% and 48.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones

- Cash, cash equivalents and marketable securities totaled $192.1 million as of March 31, 2022, with projected cash runway into the second half of 2023 -

2 weeks ago - GlobeNewsWire

Is a Surprise Coming for Sutro Biopharma (STRO) This Earnings Season?

Sutro Biopharma (STRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

3 weeks ago - Zacks Investment Research

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , April 29, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focus...

4 weeks ago - PRNewsWire

Sutro Biopharma, Inc. (STRO) Expected to Beat Earnings Estimates: Should You Buy?

Sutro Biopharma, Inc. (STRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 weeks ago - Zacks Investment Research

Sutro Biopharma Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022

SOUTH SAN FRANCISCO, Calif. , April 8, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focuse...

1 month ago - PRNewsWire

Sutro Biopharma to Present at the 21st Annual Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 5, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused...

1 month ago - PRNewsWire

Sutro Biopharma Presented on Advances in Novel Immunostimulatory Antibody-Drug Conjugate Modality at the 12th Annual ...

SOUTH SAN FRANCISCO, Calif. , March 30, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focus...

1 month ago - PRNewsWire

Sutro Biopharma, Inc. (STRO) Moves 6.4% Higher: Will This Strength Last?

Sutro Biopharma, Inc. (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength ...

2 months ago - Zacks Investment Research

Sutro Biopharma to Participate in the Cowen 42nd Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 3, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused...

2 months ago - PRNewsWire

Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused...

2 months ago - PRNewsWire

7 Triple-F-Rated Stocks That Have No Hope in Sight

The contrarian in a lot of people perks up during selloffs like the one we're in right now, but don't let these F-rated stocks tempt you. The post 7 Triple-F-Rated Stocks That Have No Hope in Sight appe...

Other symbols:CDEHYPTONRBBNSAMW
3 months ago - InvestorPlace

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRO

New York, New York--(Newsfile Corp. - February 3, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO). Such investors ...

3 months ago - Newsfile Corp

SHAREHOLDER ALERT: Investigation of Sutro Biopharma, Inc. Announced by Holzer & Holzer, LLC

Atlanta, Georgia--(Newsfile Corp. - January 18, 2022) - Holzer & Holzer, LLC is investigating whether Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO) complied with federal securities law...

4 months ago - Newsfile Corp

Why Sutro Biopharma Stock Is Losing Ground Today

Phase 1 data for its ovarian cancer candidate was a little disappointing.

4 months ago - The Motley Fool

Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 6, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused ...

4 months ago - PRNewsWire

Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advance...

SOUTH SAN FRANCISCO, Calif., Jan. 5, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused ...

4 months ago - PRNewsWire

Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China

SOUTH SAN FRANCISCO, Calif. and SHANGHAI, Dec. 27, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on ...

5 months ago - PRNewsWire

Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugat...

SOUTH SAN FRANCISCO, Calif., Dec. 27, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro"), (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicat...

5 months ago - PRNewsWire

Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021

SOUTH SAN FRANCISCO, Calif, Dec. 13, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...

5 months ago - PRNewsWire

Sutro Biopharma to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of prec...

6 months ago - PRNewsWire

Sutro Biopharma Announces Appointment of Heidi Hunter to Board of Directors

SOUTH SAN FRANCISCO, Nov. 17, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise prot...

6 months ago - PRNewsWire

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 0.00% and -3.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Sutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights, and Anticipated 2021 Milestones

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of prec...

6 months ago - PRNewsWire

Sutro Biopharma to Participate in Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...

6 months ago - PRNewsWire